Literature DB >> 20299242

Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.

Yvonne Paterson1, Patrick D Guirnalda, Laurence M Wood.   

Abstract

This review covers the use of the facultative intracellular bacteria, Listeriamonocytogenes and Salmonella enterica serovar typhimurium as delivery systems for tumor-associated antigens in tumor immunotherapy. Because of their ability to infect and survive in antigen presenting cells, these bacteria have been harnessed to deliver tumor antigens to the immune system both as bacterially expressed proteins and encoded on eukaryotic plasmids. They do this in the context of strong innate immunity, which provides the required stimulus to the immune response to break tolerance against those tumor-associated antigens that bear homology to self. Here we describe differences in the properties of these bacteria as vaccine vectors, a summary of the major therapies they have been applied to and their advancement towards the clinic. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20299242      PMCID: PMC4411241          DOI: 10.1016/j.smim.2010.02.002

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  74 in total

Review 1.  Role of pericytes in vascular morphogenesis.

Authors:  Christer Betsholtz; Per Lindblom; Holger Gerhardt
Journal:  EXS       Date:  2005

Review 2.  Invasion of mammalian cells by Listeria monocytogenes: functional mimicry to subvert cellular functions.

Authors:  Pascale Cossart; Javier Pizarro-Cerdá; Marc Lecuit
Journal:  Trends Cell Biol       Date:  2003-01       Impact factor: 20.808

3.  Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.

Authors:  Anne M Ercolini; Jean-Pascal H Machiels; Yi Cheng Chen; Jill E Slansky; Martin Giedlen; R Todd Reilly; Elizabeth M Jaffee
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

4.  Tumor angiogenesis and tissue factor.

Authors:  J Folkman
Journal:  Nat Med       Date:  1996-02       Impact factor: 53.440

5.  Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds.

Authors:  R O Schlingemann; F J Rietveld; R M de Waal; S Ferrone; D J Ruiter
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

6.  Cancer vaccines: an overview.

Authors:  Lloyd J Old
Journal:  Cancer Immun       Date:  2008-03-12

7.  Intracellular bacterial vectors that induce CD8(+) T cells with similar cytolytic abilities but disparate memory phenotypes provide contrasting tumor protection.

Authors:  Felicity C Stark; Subash Sad; Lakshmi Krishnan
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

8.  Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.

Authors:  Laurence M Wood; Patrick D Guirnalda; Matthew M Seavey; Yvonne Paterson
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

9.  Presence on a human melanoma of multiple antigens recognized by autologous CTL.

Authors:  B Van den Eynde; P Hainaut; M Hérin; A Knuth; C Lemoine; P Weynants; P van der Bruggen; R Fauchet; T Boon
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

10.  Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B.

Authors:  J Fensterle; B Bergmann; C L R P Yone; C Hotz; S R Meyer; S Spreng; W Goebel; U R Rapp; I Gentschev
Journal:  Cancer Gene Ther       Date:  2007-12-14       Impact factor: 5.987

View more
  35 in total

Review 1.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

2.  Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin.

Authors:  Christopher M Pirie; David V Liu; K Dane Wittrup
Journal:  Mol Cancer Ther       Date:  2013-07-05       Impact factor: 6.261

Review 3.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

Review 4.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

Review 5.  Immunotherapy in pancreatic cancer treatment: a new frontier.

Authors:  Komal Thind; Leslie J Padrnos; Ramesh K Ramanathan; Mitesh J Borad
Journal:  Therap Adv Gastroenterol       Date:  2016-10-17       Impact factor: 4.409

6.  An orally administered DNA vaccine targeting vascular endothelial growth factor receptor-3 inhibits lung carcinoma growth.

Authors:  Yan Chen; Xin Liu; Cong Guo Jin; Yong Chun Zhou; Roya Navab; Kristine Raaby Jakobsen; Xiao Qun Chen; Jia Li; Ting Ting Li; Lu Luo; Xi Cai Wang
Journal:  Tumour Biol       Date:  2015-09-16

Review 7.  Potential targets for pancreatic cancer immunotherapeutics.

Authors:  Lindzy F Dodson; William G Hawkins; Peter Goedegebuure
Journal:  Immunotherapy       Date:  2011-04       Impact factor: 4.196

Review 8.  Bacteria as vectors for gene therapy of cancer.

Authors:  Chwanrow K Baban; Michelle Cronin; Deirdre O'Hanlon; Gerald C O'Sullivan; Mark Tangney
Journal:  Bioeng Bugs       Date:  2010 Nov-Dec

9.  Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Authors:  Jason R Baird; Katelyn T Byrne; Patrick H Lizotte; Seiko Toraya-Brown; Uciane K Scarlett; Matthew P Alexander; Mee Rie Sheen; Barbara A Fox; David J Bzik; Marcus Bosenberg; David W Mullins; Mary Jo Turk; Steven Fiering
Journal:  J Immunol       Date:  2012-12-07       Impact factor: 5.422

Review 10.  Listeria monocytogenes: a promising vehicle for neonatal vaccination.

Authors:  Zach Z Liang; Ashley M Sherrid; Anu Wallecha; Tobias R Kollmann
Journal:  Hum Vaccin Immunother       Date:  2014-02-10       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.